Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration
Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that it was notified by the US Patent and Trade Mark Office of allowance on its first patent, US 15/002,531 “INDUCED EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) FOR TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL AND/OR METABOLIC DISEASE”. This patent allowance will help secure the path forward for the continued clinical development of MP101 in: Huntington’s Disease, Optic neuritis and Duchenne’s Muscular Dystrophy.
Mitochon Pharmaceuticals Announces Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration. “We are delighted to receive our first patent allowance. It clearly demonstrates the novelty of our work in developing mitochondrial targeted therapies for neurodegeneration. By harnessing the power of the mitochondria, our compounds are able to protect cells from the destructive effects of degeneration. Importantly, this Patent Allowance will help pave the way for human clinical development, with the hope of helping the millions of people with devastating, neurological diseases,” said Robert Alonso, co-founder and CEO of Mitochon.